In a landmark study, Lincoff et al. demonstrated that weekly subcutaneous administration of GLP-1 RA was superior to placebo in reducing cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke in patients with preexisting cardiovascular disease or overweight/obesity without diabetes [10]. The gene discussed is GLP1R; the disease is obesity disorder.